• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for ELREXFIO issued to PFIZER INC

    9/11/24 4:40:14 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PFE alert in real time by email
    Biologic License Application (BLA): 761345
    Company: PFIZER INC
    • Email
    • REMS

    Products on BLA 761345

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    ELREXFIO ELRANATAMAB 12MG SOLUTION;INJECTION Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for BLA 761345

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    08/14/2023 ORIG-1 Approval N/A; Orphan Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761345Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761345Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    09/10/2024 SUPPL-2 Supplement

    Label is not available on this site.

    12/13/2023 SUPPL-1 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761345Orig1s001ltr.pdf

    Labels for BLA 761345

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    08/14/2023 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345Orig1s000lbl.pdf
    Get the next $PFE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PFE

    DatePrice TargetRatingAnalyst
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    12/10/2024$29.00Neutral
    BofA Securities
    11/15/2024$25.00Underperform
    Wolfe Research
    10/25/2024$30.00Neutral
    Citigroup
    10/17/2024$32.00Mkt Perform
    Bernstein
    8/7/2024Neutral → Outperform
    Daiwa Securities
    3/22/2024Buy → Hold
    Argus
    2/23/2024$36.00Buy
    Guggenheim
    More analyst ratings